{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:58:08Z","timestamp":1780401488971,"version":"3.54.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejmech.2018.05.044","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T05:22:51Z","timestamp":1527830571000},"page":"459-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases"],"prefix":"10.1016","volume":"155","author":[{"given":"Mauro","family":"Ravera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-6230","authenticated-orcid":false,"given":"Elsa","family":"Moreno-Viguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Paucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-4546","authenticated-orcid":false,"given":"Silvia","family":"P\u00e9rez-Silanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-1955","authenticated-orcid":false,"given":"Elisabetta","family":"Gabano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.05.044_bib1","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.05.044_bib2","author":"CDC"},{"key":"10.1016\/j.ejmech.2018.05.044_bib3","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"217","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib4","series-title":"World Health Organization Technical Report Series","first-page":"1","article-title":"Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis","author":"WHO","year":"2012"},{"key":"10.1016\/j.ejmech.2018.05.044_bib5","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(03)14694-6","article-title":"The trypanosomiases","volume":"362","author":"Barrett","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.05.044_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1590\/0074-02760150253","article-title":"Exploring the environmental diversity of kinetoplastid flagellates in the high-throughput DNA sequencing era","volume":"110","author":"d'Avila-Levy","year":"2015","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ejmech.2018.05.044_bib7","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.2174\/0929867323999160625124424","article-title":"Challenges in Chagas disease drug discovery: a review","volume":"23","author":"Paucar","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib8","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.05.044_bib9","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.05.044_bib10","author":"WHO"},{"issue":"5","key":"10.1016\/j.ejmech.2018.05.044_bib11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and clinical treatment of Chagas disease: a review","volume":"97","author":"Sales Junior","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2018.05.044_bib12","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.05.044_bib13","author":"CDC"},{"key":"10.1016\/j.ejmech.2018.05.044_bib14","author":"DNDi"},{"key":"10.1016\/j.ejmech.2018.05.044_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003244","article-title":"First WHO meeting of stakeholders on elimination of gambiense human African trypanosomiasis","volume":"8","author":"Holmes","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.05.044_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib17","author":"CDC"},{"key":"10.1016\/j.ejmech.2018.05.044_bib18","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.05.044_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host\u2013pathogen interface","volume":"9","author":"Kaye","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib21","first-page":"581","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis, Nature Reviews","volume":"16","author":"Scott","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2018.05.044_bib22","series-title":"World Health Organization, Web Server without Geographic Relation","article-title":"Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected diseases 2015","author":"W.D.o.c.o.n.t. diseases","year":"2015"},{"key":"10.1016\/j.ejmech.2018.05.044_bib23","author":"DNDi"},{"key":"10.1016\/j.ejmech.2018.05.044_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib25","author":"DNDi"},{"key":"10.1016\/j.ejmech.2018.05.044_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000440","article-title":"Advancing drug innovation for neglected diseases-criteria for lead progression","volume":"3","author":"Nwaka","year":"2009","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.05.044_bib27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd2144","article-title":"Innovative lead discovery strategies for tropical diseases, Nature Reviews","volume":"5","author":"Nwaka","year":"2006","journal-title":"Drug Discovery"},{"key":"10.1016\/j.ejmech.2018.05.044_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000440","article-title":"Advancing drug innovation for neglected diseases\u2014criteria for lead progression","volume":"3","author":"Nwaka","year":"2009","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.05.044_bib29","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1039\/c3cc41143e","article-title":"Exploration of the medical periodic table: towards new targets","volume":"49","author":"Barry","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2018.05.044_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/156802612799078964","article-title":"Next-generation anticancer metallodrugs","volume":"12","author":"Seiji","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib31","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ccr.2013.01.031","article-title":"Review: emerging protein targets for metal-based pharmaceutical agents: an update","volume":"257","author":"de Almeida","year":"2013","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib32","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1021\/cr400460s","article-title":"Metallodrugs in medicinal inorganic chemistry","volume":"114","author":"Mjos","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccr.2014.08.002","article-title":"Noble metals in medicine: latest advances","volume":"284","author":"Medici","year":"2015","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1389557043487493","article-title":"Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis","volume":"4","author":"Sanchez-Delgado","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.drudis.2010.10.005","article-title":"Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives","volume":"15","author":"Navarro","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.05.044_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ica.2012.05.028","article-title":"Review: perspectives on what ruthenium-based compounds could offer in the development of potential antiparasitic drugs","volume":"393","author":"Gambino","year":"2012","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2018.05.044_bib37","series-title":"TW (Ed.) Comprehensive Inorganic Chemistry II: from Elements to Applications","first-page":"975","article-title":"Metal complexes in the treatment of tropical diseases: malaria, trypanosomiasis, and leishmaniasis","author":"Wang","year":"2013"},{"key":"10.1016\/j.ejmech.2018.05.044_bib38","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1039\/C4DT00022F","article-title":"Gold complexes as antimicrobial agents: an overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure","volume":"43","author":"Glisic","year":"2014","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2018.05.044_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ica.2017.07.068","article-title":"Design of prospective antiparasitic metal-based compounds including selected organometallic cores","volume":"472","author":"Gambino","year":"2018","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2018.05.044_bib40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2010.3663","article-title":"Anticancer activity of metal complexes: involvement of redox processes","volume":"15","author":"Jungwirth","year":"2011","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2018.05.044_bib41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.13.5.735","article-title":"Trypanocidal activity of antitumor Antibiotics and other metabolic inhibitors","volume":"13","author":"Williamson","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.05.044_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/AAC.15.2.157","article-title":"Activity of antitumor drugs against African trypanosomes","volume":"15","author":"Kinnamon","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.05.044_bib43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0006-2952(84)90501-X","article-title":"Trypanocidal and antitumour activity of platinum-metal and platinum-metal-drug dual-function complexes","volume":"33","author":"Farrell","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib44","series-title":"Nomenclature of Inorganic Chemistry : IUPAC Recommendations 2005","author":"Connelly","year":"2005"},{"key":"10.1016\/j.ejmech.2018.05.044_bib45","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/bph.12688","article-title":"Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs)","volume":"172","author":"Schatzschneider","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib46","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials: new perspectives for old drugs","volume":"14","author":"Frezard","year":"2009","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.ejmech.2018.05.044_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1039\/B707077M","article-title":"Bioorganometallic chemistry-from teaching paradigms to medicinal applications","volume":"38","author":"Hartinger","year":"2009","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1021\/om100964h","article-title":"Bioorganometallics: future trends in drug discovery, analytical chemistry, and catalysis","volume":"30","author":"Hillard","year":"2011","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2018.05.044_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbpa.2012.01.013","article-title":"The potential of organometallic complexes in medicinal chemistry","volume":"16","author":"Gasser","year":"2012","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ica.2017.05.021","article-title":"Transition metal carbonyl clusters in biology: a futile or niche research area?","volume":"470","author":"Arrais","year":"2018","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2018.05.044_bib51","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1039\/C5MD00174A","article-title":"Medicinal organometallic chemistry - an emerging strategy for the treatment of neglected tropical diseases","author":"Brown","year":"2015","journal-title":"Med. Chem.Communications"},{"key":"10.1016\/j.ejmech.2018.05.044_bib52","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1039\/C6MD00200E","article-title":"Medicinal organometallic compounds with anti-chagasic activity","volume":"7","author":"Camarada","year":"2016","journal-title":"Med. Chem.Communications"},{"key":"10.1016\/j.ejmech.2018.05.044_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/13543784.2015.1000483","article-title":"Antimalarial compounds in Phase II clinical development","volume":"24","author":"Held","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2018.05.044_bib54","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ccr.2008.04.014","article-title":"Functionalised \u03b76-arene ruthenium complexes","volume":"253","author":"Therrien","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib55","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm300070h","article-title":"Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in\u00a0vitro activity against leishmania major and trypanosoma cruzi and low toxicity toward normal mammalian cells","volume":"55","author":"Mart\u00ednez","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.actatropica.2016.09.029","article-title":"Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis","volume":"164","author":"Iniguez","year":"2016","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2018.05.044_bib57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00775-013-1024-2","article-title":"Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells","volume":"18","author":"Iniguez","year":"2013","journal-title":"J.\u00a0Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib58","first-page":"169","article-title":"Spectroscopic study of the interactions of ruthenium-ketoconazole complexes of known antiparasitic activity with human serum albumin and Apotransferrin","volume":"57","author":"Jes\u00fas G","year":"2013","journal-title":"Journal of the Mexican Chemical Society"},{"key":"10.1016\/j.ejmech.2018.05.044_bib59","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1002\/chem.201303341","article-title":"DMSO-mediated ligand dissociation: renaissance for biological activity of N-Heterocyclic-[Ru(6-arene)Cl2] drug candidates","volume":"19","author":"Patra","year":"2013","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2018.05.044_bib60","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1021\/acs.jmedchem.5b00403","article-title":"Cyclopentadienyl-ruthenium(II) and iron(II) organometallic compounds with carbohydrate derivative ligands as good colorectal anticancer agents","volume":"58","author":"Florindo","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib61","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1080\/00958972.2015.1062480","article-title":"A\u00a0new ruthenium cyclopentadienyl azole compound with activity on tumor cell lines and trypanosomatid parasites","volume":"68","author":"Esteban Rodrguez","year":"2015","journal-title":"J.\u00a0Coord. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib62","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1021\/acs.organomet.5b00458","article-title":"Of Manganese(I) tricarbonyl complexes with ketoconazole, miconazole, and clotrimazole ligands","volume":"34","author":"Simpson","year":"2015","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2018.05.044_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874846501003020016","article-title":"Thiosemicarbazone metal complexes: from structure to activity","volume":"3","author":"Pelosi","year":"2010","journal-title":"Open Crystallogr. J."},{"key":"10.1016\/j.ejmech.2018.05.044_bib64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0006-2952(98)00324-4","article-title":"Enzymatic reduction studies of nitroheterocycles","volume":"57","author":"Viod\u00e9","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib65","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1039\/C1DT11519G","article-title":"New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents","volume":"41","author":"Demoro","year":"2012","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2018.05.044_bib66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12011-013-9653-4","article-title":"Potential mechanism of the anti-trypanosomal activity of organoruthenium complexes with bioactive thiosemicarbazones","volume":"153","author":"Demoro","year":"2013","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.ejmech.2018.05.044_bib67","first-page":"4677","article-title":"Effect of the metal ion on the anti T. cruzi activity and mechanism of action of 5-nitrofuryl-containing thiosemicarbazone metal complexes","author":"Crans","year":"2014","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12011-014-9964-0","article-title":"Water-soluble ruthenium complexes bearing activity against Protozoan parasites","volume":"159","author":"Sarniguet","year":"2014","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.ejmech.2018.05.044_bib69","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jinorgbio.2015.06.018","article-title":"Novel ruthenium(II) cyclopentadienyl thiosemicarbazone compounds with antiproliferative activity on pathogenic trypanosomatid parasites","volume":"153","author":"Fern\u00e1ndez","year":"2015","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jinorgbio.2017.01.011","article-title":"Rhenium(I) tricarbonyl compounds of bioactive thiosemicarbazones: synthesis, characterization and activity against Trypanosoma cruzi","volume":"170","author":"Rodr\u00edguez Arce","year":"2017","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib71","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/1681039b0","article-title":"A\u00a0new type of organo-iron compound","volume":"168","author":"Kealy","year":"1951","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.05.044_bib72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1039\/jr9520000632","article-title":"Dicyclopentadienyliron","author":"Miller","year":"1952","journal-title":"J.\u00a0Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.05.044_bib73","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1021\/cr0101510","article-title":"Bioorganometallic chemistry of ferrocene","volume":"104","author":"van Staveren","year":"2004","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib74","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/0041-008X(69)90067-2","article-title":"Chronic toxicity of dicyclopentadienyliron (ferrocene) in dogs","volume":"15","author":"Yeary","year":"1969","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib75","series-title":"Medicinal Organometallic Chemistry","first-page":"81","article-title":"Ferrocene functionalized endocrine modulators as anticancer agents","author":"Hillard","year":"2010"},{"key":"10.1016\/j.ejmech.2018.05.044_bib76","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1039\/C5CS00486A","article-title":"Ferrocifen type anti cancer drugs","volume":"44","author":"Jaouen","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib77","series-title":"Medicinal Organometallic Chemistry","first-page":"155","article-title":"Bioorganometallic chemistry and malaria","author":"Biot","year":"2010"},{"key":"10.1016\/j.ejmech.2018.05.044_bib78","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejmech.2015.07.009","article-title":"Ferroquine and its derivatives: new generation of antimalarial agents","volume":"101","author":"Wani","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib79","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00436-012-3183-4","article-title":"Antiprotozoal activity of ferroquine","volume":"112","author":"Pomel","year":"2013","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejmech.2018.05.044_bib80","doi-asserted-by":"crossref","first-page":"15896","DOI":"10.1038\/s41598-017-16154-2","article-title":"Ferroquine, the next generation antimalarial drug, has antitumor activity","volume":"7","author":"Kondratskyi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.05.044_bib81","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/cr00081a012","article-title":"Non-platinum group metal antitumor agents. History, current status, and perspectives","volume":"87","author":"Koepf-Maier","year":"1987","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic anticancer compounds","volume":"54","author":"Gasser","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib83","series-title":"Ferrocenes: Ligands, Materials and Biomolecules","article-title":"The bioorganometallic chemistry of ferrocene","author":"Metzler-Nolte","year":"2008"},{"key":"10.1016\/j.ejmech.2018.05.044_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jmgm.2013.12.001","article-title":"Homology modeling of T. cruzi and L. major NADH-dependent fumarate reductases: ligand docking, molecular dynamics validation, and insights on their binding modes","volume":"48","author":"Merlino","year":"2014","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2018.05.044_bib85","series-title":"Parasite Mitochondria as Drug Target: Diversity and Dynamic Changes during the Life Cycle","author":"Kita","year":"2003"},{"key":"10.1016\/j.ejmech.2018.05.044_bib86","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s11095-011-0586-3","article-title":"Mitochondria and trypanosomatids: targets and drugs","volume":"28","author":"Fidalgo","year":"2011","journal-title":"Pharmaceut. Res."},{"key":"10.1016\/j.ejmech.2018.05.044_bib87","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbagen.2011.12.013","article-title":"Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells","volume":"1820","author":"Sakai","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2018.05.044_bib88","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1039\/C5DT00557D","article-title":"Aromatic amine N-oxide organometallic compounds: searching for prospective agents against infectious diseases","volume":"44","author":"Arce","year":"2015","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2018.05.044_bib89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.poly.2017.05.003","article-title":"Palladium(II)\/N,N-disubstituted-N\u2032-acylthioureas complexes as anti-Mycobacterium tuberculosis and anti-Trypanosoma cruzi agents","volume":"132","author":"Plut\u00edn","year":"2017","journal-title":"Polyhedron"},{"key":"10.1016\/j.ejmech.2018.05.044_bib90","first-page":"3238","article-title":"Synthesis, characterization and anti-Trypanosoma cruzi evaluation of ferrocenyl and cyrhetrenyl imines derived from 5-nitrofurane","volume":"696","author":"Arancibia","year":"2011","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jorganchem.2013.06.014","article-title":"Organometallic Schiff bases derived from 5-nitrothiophene and 5-nitrofurane: synthesis, crystallographic, electrochemical, ESR and antiTrypanosoma cruzi studies","volume":"743","author":"Rodrigo Arancibia","year":"2013","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib92","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1021\/jm701306r","article-title":"Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy","volume":"51","author":"Silva","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib93","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10534-016-9953-1","article-title":"The characterization of anti-T. cruzi activity relationships between ferrocenyl, cyrhetrenyl complexes and ROS release","volume":"29","author":"Echeverria","year":"2016","journal-title":"Biometals"},{"key":"10.1016\/j.ejmech.2018.05.044_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jorganchem.2013.12.049","article-title":"Synthesis, characterization and in\u00a0vitro anti-Trypanosoma cruzi and anti-Mycobacterium tuberculosis evaluations of cyrhetrenyl and ferrocenyl thiosemicarbazones","volume":"755","author":"Arancibia","year":"2014","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib95","first-page":"303","article-title":"Cymantrene, cyrhetrene and ferrocene nucleobase conjugates: synthesis, structure, computational study, electrochemistry and antitrypanosomal activity","volume":"82","author":"Kowalski","year":"2017","journal-title":"Chem Plus Chem"},{"key":"10.1016\/j.ejmech.2018.05.044_bib96","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1021\/cr0781059","article-title":"Square-planar Pd(II), Pt(II), and Au(III) terpyridine complexes: their syntheses, physical properties, supramolecular constructs, and biomedical activities","volume":"108","author":"Eryazici","year":"2008","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejmech.2014.01.051","article-title":"Synthesis of 4\u2032-(2-ferrocenyl)-2,2\u2032:6\u20322\u2032\u2032-terpyridine: characterization and antiprotozoal activity of Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes","volume":"75","author":"Juneja","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib98","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","article-title":"Primaquine revisited six decades after its discovery","volume":"44","author":"Vale","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib99","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/AAC.00873-12","article-title":"Peptidomimetic and organometallic derivatives of primaquine active against leishmania infantum","volume":"56","author":"Vale-Costa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.05.044_bib100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jorganchem.2013.07.044","article-title":"Synthesis, structural characterization and leishmanicidal activity evaluation of ferrocenyl N-heterocyclic compounds","volume":"745\u2013746","author":"Quintal","year":"2013","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib101","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis","volume":"114","author":"Nagle","year":"2014","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.ejmech.2018.05.044_bib102","doi-asserted-by":"crossref","first-page":"11442","DOI":"10.1073\/pnas.91.24.11442","article-title":"PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the Protozoan parasite leishmania major","volume":"91","author":"Bello","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.05.044_bib103","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2014.12.051","article-title":"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies","volume":"92","author":"Mendoza-Mart\u00ednez","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib104","unstructured":"N.d.C. Galindo Sevilla, F. Hern\u00e1ndez Luis, Patent EP 2 599 783 A1, 2011."},{"key":"10.1016\/j.ejmech.2018.05.044_bib105","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.bmcl.2014.02.046","article-title":"Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi","volume":"24","author":"Velasquez","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.05.044_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm000084m","article-title":"Terminally alkylated polyamine analogues as chemotherapeutic agents","volume":"44","author":"Casero","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib107","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/cbdd.12191","article-title":"Assessment of leishmanicidal and trypanocidal activities of aliphatic diamine derivatives","volume":"82","author":"Yamanaka","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.05.044_bib108","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.01796-10","article-title":"Selective inhibitors of Methionyl-tRNA synthetase have potent activity against trypanosoma brucei infection in mice","volume":"55","author":"Shibata","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.05.044_bib109","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/cmdc.201402537","article-title":"Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent","volume":"10","author":"Yousuf","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.05.044_bib110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2016.08.049","article-title":"Antileishmanial ferrocenylquinoline derivatives: synthesis and biological evaluation against Leishmania donovani","volume":"124","author":"Yousuf","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib111","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1002\/anie.201303690","article-title":"The ferroquine antimalarial conundrum: redox activation and reinvasion inhibition","volume":"52","author":"Dubar","year":"2013","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib112","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2174\/1568026614666140808122329","article-title":"Ferroquine as an oxidative shock antimalarial","volume":"14","author":"Dive","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib113","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.1039\/c2dt30077j","article-title":"Synthesis and biological activity of cymantrene and cyrhetrene 4-aminoquinoline conjugates against malaria, leishmaniasis, and trypanosomiasis","volume":"41","author":"Glans","year":"2012","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2018.05.044_bib114","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1021\/om4007642","article-title":"Cymantrene-triazole \"click\" products: structural characterization and electrochemical properties","volume":"33","author":"Day","year":"2014","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2018.05.044_bib115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ardp.201500312","article-title":"Antileishmanial, DNA interaction, and docking studies of some ferrocene-based heteroleptic pentavalent antimonials","volume":"349","author":"Rauf","year":"2016","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2018.05.044_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2008.12.003","article-title":"Gold complexes as potential anti-parasitic agents","volume":"253","author":"Navarro","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib117","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1039\/c1mt00062d","article-title":"Gold compounds as therapeutic agents for human diseases","volume":"3","author":"Berners-Price","year":"2011","journal-title":"Metall"},{"key":"10.1016\/j.ejmech.2018.05.044_bib118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/156802611798040732","article-title":"Molecular mechanisms and proposed targets for selected anticancer gold compounds","volume":"11","author":"Casini","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib119","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1039\/C5CS00132C","article-title":"Chemical biology of anticancer gold((III)) and gold((I)) complexes","volume":"44","author":"Zou","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2018.05.044_bib120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev.mi.46.100192.003403","article-title":"Metabolism and functions of trypanothione in the Kinetoplastida","volume":"46","author":"Fairlamb","year":"1992","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib121","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.mib.2004.06.010","article-title":"Cysteine peptidases as virulence factors of Leishmania","volume":"7","author":"Mottram","year":"2004","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib122","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/17460441.2012.668520","article-title":"Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease","volume":"7","author":"Nicoll-Griffith","year":"2012","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.05.044_bib123","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/138945009787581140","article-title":"Approaches for the development of new anti-trypanosoma cruzi agents","volume":"10","author":"Magalhaes Moreira","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2018.05.044_bib124","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/978-1-4419-8414-2_7","article-title":"Cruzain: the path from target validation to the clinic","volume":"712","author":"Sajid","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib125","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/cb400800q","article-title":"Auranofin is an apoptosis-simulating agent with in\u00a0vitro and in\u00a0vivo anti-leishmanial activity","volume":"9","author":"Sharlow","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib126","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.exppara.2015.05.012","article-title":"F.d.F. Anibal, O.H. Thiemann, in\u00a0vivo and in\u00a0vitro auranofin activity against Trypanosoma cruzi: possible new uses for an old drug","volume":"166","author":"da Silva","year":"2016","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib127","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1093\/nar\/gkl541","article-title":"Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein","volume":"34","author":"Lobanov","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2018.05.044_bib128","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00726-011-0997-9","article-title":"A\u00a0gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition","volume":"42","author":"Ilari","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejmech.2018.05.044_bib129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/b924677k","article-title":"Cysteine proteases as targets for metal-based drugs","volume":"2","author":"Fricker","year":"2010","journal-title":"Metall"},{"key":"10.1016\/j.ejmech.2018.05.044_bib130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10534-017-0007-0","article-title":"Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents","volume":"30","author":"Massai","year":"2017","journal-title":"Biometals"},{"key":"10.1016\/j.ejmech.2018.05.044_bib131","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1039\/C6DT04307K","article-title":"Organometallic gold(iii) complexes with hybrid SNS-donating thiosemicarbazone ligands: cytotoxicity and anti-Trypanosoma cruzi activity","volume":"46","author":"Maia","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2018.05.044_bib132","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nature13384","article-title":"An overview of N-heterocyclic carbenes","volume":"510","author":"Hopkinson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.05.044_bib133","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1039\/C2CS35314H","article-title":"Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs","volume":"42","author":"Liu","year":"2013","journal-title":"Chemical Society Reviews"},{"key":"10.1016\/j.ejmech.2018.05.044_bib134","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejmech.2015.02.046","article-title":"Synthesis, characterization, and antileishmanial activities of gold(I) complexes involving quinoline functionalized N-heterocyclic carbenes","volume":"94","author":"Paloque","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib135","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.ejmech.2017.10.060","article-title":"Synthesis, characterization, and antileishmanial activity of neutral N-heterocyclic carbenes gold(I) complexes","volume":"143","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib136","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molbiopara.2017.05.001","article-title":"Anti-trypanosomal activity of cationic N-heterocyclic carbene gold(I) complexes","volume":"214","author":"Winter","year":"2017","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2018.05.044_bib137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jinorgbio.2015.06.007","article-title":"Antitumor and antiparasitic activity of novel ruthenium compounds with polycyclic aromatic ligands","volume":"150","author":"Miserachs","year":"2015","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib138","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1002\/ejic.201300820","article-title":"Synthesis, cellular uptake and biological activity against pathogenic microorganisms and cancer cells of rhodium and iridium N-heterocyclic carbene complexes bearing charged substituents","author":"Simpson","year":"2013","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib139","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jorganchem.2016.06.013","article-title":"New platinum(II) complexes of CCC-pincer N-heterocyclic carbene ligand: synthesis, characterization, cytotoxicity and antileishmanial activity","volume":"818","author":"Tabrizi","year":"2016","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib140","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2174\/092986706776872970","article-title":"Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin","volume":"13","author":"Abu-Surrah","year":"2006","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.ejmech.2018.05.044_bib141","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jinorgbio.2008.05.010","article-title":"Metal compounds for the treatment of parasitic diseases","volume":"102","author":"Fricker","year":"2008","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2018.05.044_bib142","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1128\/AAC.00323-10","article-title":"In\u00a0vitro and in\u00a0vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease","volume":"54","author":"Matsuo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.05.044_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001626","article-title":"In\u00a0vitro and in\u00a0vivo activity of a palladacycle complex on leishmania (leishmania) amazonensis","volume":"6","author":"Paladi","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.05.044_bib144","first-page":"1032","article-title":"Antiprotozoal activity of the cyclopalladated complexes against leishmania amazonensis and trypanosoma cruzi","volume":"27","author":"Angela M. A","year":"2016","journal-title":"J.\u00a0Braz. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.05.044_bib145","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00044-012-0095-x","article-title":"Palladium(II) imine ligands cyclometallated complexes with a potential leishmanicidal activity on Leishmania (L.) amazonensis","volume":"22","author":"Franco","year":"2013","journal-title":"Med. Chem. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418304574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418304574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T09:46:19Z","timestamp":1569059179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418304574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":145,"alternative-id":["S0223523418304574"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.044","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}